Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Zoledronic Acid in Newly Diagnosed Multiple Myeloma
NCT01345019Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2012
- Primary completion
- Jul 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of denosumab in multiple myeloma (MM), sponsored by Amgen. Started May 2012; status: completed.
02
Drugs
denosumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01345019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01345019.